Core Viewpoint - The stock of Insilico Medicine (03696) surged over 11% on its second day of trading, reaching HKD 33.62, nearly a 40% increase from its IPO price of HKD 24.05 [1][3] Company Overview - Insilico Medicine was established in 2014 and is a leading company in AI-driven drug discovery and development in China [1][3] - As of December 10, 2025, the company has generated over 20 assets in clinical or IND application stages through its proprietary generative AI platform, Pharma.AI [1][3] Business Developments - Three of the assets have been licensed to international pharmaceutical companies, with a total contract value of up to USD 2.1 billion [1][3] - The company also has one asset in the II phase of independent development, which is considered to be at a leading stage in the industry [1][3] Market Performance - As of the latest update, the stock price increased by 11.74%, currently trading at HKD 33.50, with a trading volume of HKD 94.5447 million and a total market capitalization exceeding HKD 18 billion [1][3]
英矽智能上市次日涨近12% 较招股价涨近4成